Jump to ContentJump to Main Navigation
An Insider’s Guide to Clinical Trials$

Curtis L Meinert

Print publication date: 2011

Print ISBN-13: 9780199742967

Published to Oxford Scholarship Online: September 2011

DOI: 10.1093/acprof:oso/9780199742967.001.0001

Show Summary Details
Page of

PRINTED FROM OXFORD SCHOLARSHIP ONLINE (www.oxfordscholarship.com). (c) Copyright Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a monograph in OSO for personal use (for details see http://www.oxfordscholarship.com/page/privacy-policy). Subscriber: null; date: 08 December 2016

(p.247) References

(p.247) References

Source:
An Insider’s Guide to Clinical Trials
Publisher:
Oxford University Press

Bibliography references:

1. ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800–1808.

ch3, ch4, ch14

2. ADAPT Research Group. Cardiovascular and cerebrovascular results from the randomized, controlled Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006; 1(7):e33.

ch13, ch14

3. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med. 2001; 134:663–694.

ch13, ch15, appB

4. Amberson JB, Jr., McMahon BT, Pinner M. A clinical trial of sanocrysin in pulmonary tuberculosis. Am Rev Tuberc. 1931; 24:401–435.

ch1

5. American Bible Society. The Holy Bible: Old and New Testaments. King James Version (1611). New York: 1816.

ch1

6. Angell M. Industry-sponsored clinical research: A broken system. JAMA. 2008; 300:1069–1071.

ch11

7. Angell M. Investigators’ responsibility for human subjects in developing countries. N Engl J Med. 2000; 342:967–969.

ch11

(p.248) 8. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324:71–86.

ch18, ch19

9. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994; 308:81–106.

ch19

10. Antman EM, Lau J, Kupeinick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. JAMA. 1992; 268:240–248.

ch18

11. Bailey KR. Detecting fabrication of data in a multicenter collaborative animal study. Control Clin Trials. 1991; 12:741–752.

ch10

12. Baron J. The life of Edward Jenner: With illustrations of his doctrines and selections from his correspondence (book review). Br Foreign Med Rev. 1838; 6:477–497.

ch22

13. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006; 98:746–750.

ch19

14. Beecher HK. Ethics and clinical research. N Engl J Med. 1966; 274:1354–1360.

ch8

15. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schultz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA. 1996; 276:637–639.

ch9

16. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA. 2006; 295:306–313.

ch19

17. Black’s Law Dictionary. St. Paul, MN: West Publishing Company, 1990.

ch10

18. Box JF. RA Fisher and the design of experiments, 1922–1926. Am Statistician. 1980; 34:1–7.

ch1

(p.249) 19. Broad WJ.: U.S. to penalize heart researchers on fraudulent project at Harvard. New York Times. 16 February 1983.

ch10

20. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Pub Health. 1998; 88:1337–1342.

ch12

21. Canner PL. Aspirin in coronary heart disease: Comparison of six clinical trials. Isr J Med Sci. 1983; 19:413–423.

ch19

22. Childhood Asthma Management Program Research Group. The Childhood Asthma Management Program (CAMP): Design, rationale, and methods. Control Clin Trials. 1999; 20:91–120.

ch4

23. Collins JF, Garg R, Koon KT, Williford WO, Howell CL on behalf of DIG Investigators. The role of the data coordinating center in the IRB review and approval process: The DIG trial experience. Control Clin Trials. 2003; 24:306S–315S.

ch8

24. Colsky J. Clinical investigator: The clinical investigator and evaluation of new drugs. Am J Hosp Pharm. 1963; 20:517–519.

ch1

25. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337:581–588.

ch24

26. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O’Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J., for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994; 331:1173–1180.

ch11, ch19

27. Cornfield J. Recent methodological contributions to clinical trials. Am J Epidemiol. 1976; 104:408–421.

ch11, ch17

28. Cornfield J. Design of clinical trials. In Goldstein M, ed., Research Status of Spinal Manipulative Therapy, pp. 303–306. Monograph no. 15. Bethesda, MD: National Institute of Neurological and Communicative Disorders and Stroke, 1975.

ch15

(p.250) 29. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975; 231:360–381.

ch4

30. Coronary Drug Project Research Group. The Coronary Drug Project: Design, methods, and baseline results. Circulation. 1973; 47(Suppl I):I-1–I-50.

ch5, ch16

31. Couzin J. Drug testing: Massive trial of Celebrex seeks to settle safety concerns. Science. 2005; 310:1890–1891.

ch19

32. Creighton C. A history of epidemics in Britain: From the extinction of plague to the present time (vol. II). Cambridge: The University Press, 1894.

ch22

33. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: The adverse effects of industry influence. JAMA. 2008; 299:1833–1835.

ch6, ch13

34. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJPM, Schroeder TV, Sox HC, Van Der Weyden MB: Clinical trial registration: A statement from the International Committee of Medical Journal Editors. JAMA. 2004; 292:1363–1364.

ch9

35. Department of Health and Human Services. Public Health Services policies on research misconduct; 42 CFR Parts 50 and 93. Federal Register. 2005; 70:28370–28400.

ch10

36. Dieckmann WJ, Davis ME, Rynkiewicz LM, Pottinger RE. Does the administration of diethylstilbestrol during pregnancy have therapeutic value?. Am J Obst Gynecol. 1953; 66:1062–1081.

ch24

37. Diehl HS, Baker AB, Cowan DW. Cold vaccines: An evaluation based on a controlled study JAMA. 1938; 111:1168–1173.

ch1

38. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336:525–533.

ch6, ch8

39. Drummond JC, Wilbraham A. The Englishman’s food: A history of five centuries of English diet. London: Jonathan Cape, 1940.

ch1

40. Fenner F, Henderson DA, Arita I, Landyi ID. Smallpox and its eradication. Geneva: World Health Organization, 1988.

ch22

(p.251) 41. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding? Clin Trials. 2005; 2:218–232.

ch19

42. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1995; 333:1456–1451.

ch10

43. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, et al: Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985; 312:665–73.

ch10

44. Fisher RA. Statistical methods and scientific inference (3rd edition). New York: Hafner Press, Macmillan Publishing Co., 1973.

ch1

45. Fisher RA. The arrangement of field experiments. J Ministry Agric Great Britain. 1926; 33:503–513.

ch1

46. Fisher RA, MacKenzie WA. Studies in crop variation: II. The manurial response of different potato varieties. J Agric Sci. 1923; 13:311–320.

ch1

47. Food and Drug Administration. Procedural and interpretative regulations: Investigational use. Federal Register. January 8, 1963; 28:179–182.

ch1

48. Fost N, Levine RJ. The dysregulation of human subjects research. JAMA. 2008; 298:2196–2198.

ch11

49. Francis T, Korns RF, Voigt RB, Boisen M, Hemphill FM, Napier JA, Tolchinsky E. An evaluation of the 1954 poliomyelitis vaccine trial: Summary report. Am J Public Health. 1955; 45(Part II, May Suppl):1–51.

ch1

50. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987; 317:141–145.

ch8

51. Freedman LS, Simon R, Foulkes MA, Friedman L, Geller NL, Gordon DJ, Mowery R. Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993—The perspective of NIH clinical trialists (with discussion and response). Control Clin Trials. 1995;16:277–312.

ch11

(p.252) 52. Freis ED. Historical development of antihypertensive treatment. In Laragh JH, Brenner BM, eds., Hypertension pathophysiology, diagnosis, and management, 2nd ed., Chapter 164, pp. 2741–2751. New York: Raven Press, 1995.

ch19

53. Glass GV. Primary, secondary and meta-analysis of research. Educational Researcher. 1976; 5:3–8.

ch18

54. Goodman SN. Toward evidence-based medical statistics. 1: The p value fallacy. Ann Intern Med. 1995; 130:995–1004.

ch16

55. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jacksom JB: Intrapartum and neonatal single-dose nevirapine with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999; 354:795–802.

ch11

56. Hayes SN, Redberg RF. Dispelling the myths: Calling for sex-specific reporting of trials results. Mayo Clin Proc. 2008; 83:523–525.

ch8

57. Haygarth J. Of the imagination, as a cause and as a cure of disorders of the body: Exemplified by fictitious tractors, and epidemical convulsions. Bath: R Cruttwell, 1800.

ch2

58. Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas (so-called mesonephromas). Cancer. 1970; 25:745–757.

ch24

59. Hill AB. Statistical methods in clinical and preventive medicine. New York: Oxford University Press, 1962.

ch1

60. Huff D. How to lie with statistics. Illustrated, I Geis. New York: Norton, 1954.

ch13

61. Hypertension Detection and Follow-Up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-Up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979a; 242:2562–2571.

ch1

62. Hypertension Detection and Follow-up Program. Therapeutic control of blood pressure in the Hypertension Detection and Follow-up Program. Prev Med. 1979; 8:2–13.

ch13

(p.253) 63. Hypertension Prevention Trial Research Group, C Meinert, J Tonascia, S Tonasica, eds. The Hypertension Prevention Trial (HPT): Design, methods, and baseline results. Control Clin Trials. 1989; 10 (Suppl):1S–17S.

ch10

64. Ibarreta D, Swan SH: The DES story: Long-term consequences of prenatal exposure. In Harremoës P, Gee D, MacGarvin M, Stirling A, Keys J, Wynne B, Vaz SG, eds. Late lessons from early warnings: The precautionary principle 1896–2000. Chapter 8, pp. 84–91. Copenhagen: European Environment Agency, 2001.

ch24

65. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med. 1997; 336:309–315.

ch6

66. Jenner E. An inquiry into the causes and effects of the variolae vaccine. London: Sampson Low, 1798.

ch22

67. Johnson S. A dictionary of the English language. (2 vols.). Printed by W Strahan, for J and P Knapton; T and T Longman; C Hitch and L Hawes; A Millar; and R and J Dodsley, 1755.

ch2

68. Kassirer JP, Angell M. On authorship and acknowledgments. N Engl J Med. 1991; 325:1510–1512.

ch6

69. Kelsey FO. Government: The Kefauver-Harris Amendments and investigational drugs. Am J Hosp Pharm. 1963; 20:515–517.

ch1

70. Kluger J. Splendid solution: Jonas Salk and the conquest of polio. New York: Penguin Group (USA), 2005.

ch22

71. Last JM. A dictionary of epidemiology (4th edition). New York: Oxford University Press, 2001.

ch16

72. Levine RJ. Ethics and regulation of clinical research (2nd edition). New Haven: Yale University Press, 1988.

ch8, ch9

73. Lewis S, Clarke M.: Forest plots: Trying to see the wood and the trees. BMJ. 2001;322:1479–1480.

ch18

74. Lind J. A treatise of the scurvy (reprinted in Lind’s Treatise on scurvy, edited by CP Stewart, D Guthrie, Edinburgh University Press, Edinburgh, 1953). Edinburgh: Sands, Murray, Cochran, 1753.

ch1

(p.254) 75. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148:197–213.

ch18

76. Markel H. April 12, 1955 – Tommy Francis and the Salk Vaccine. N Engl J Med. 2005; 352:1408–1410.

ch1

77. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation. Br Med J. 1948; 2:769–782.

ch1

78. Medical Research Council. Clinical trials of new remedies (annotations). Lancet. 1931; 2:304.

ch1

79. Meinert C, Gilpin AK, Ünalp A, Dawson C. Gender representation in trials. Control Clin Trials. 2000; 21:462–475.

ch11

80. Meinert CL. Controlled Clinical Trials (the journal). Encyclopedia of biostatistics, vol. 1, pp. 929–931. Chichester, UK: John Wiley & Sons,1998.

ch1

81. Meinert CL. Beyond CONSORT: Need for improved reporting standards for clinical trials. JAMA. 1998; 279:1487–1489.

ch9

82. Meinert CL. Masked monitoring in clinical trials—Blind stupidity?. N Engl J Med. 1998; 338:1381–1382.

ch11, ch23, ch24

83. Meinert CL. Clinical trials dictionary: Terminology and usage recommendations. Baltimore, MD: The Johns Hopkins Center for Clinical Trials, 1996.

v, ch2, ch10

84. Meinert CL, Tonascia S. Clinical trials:Design, conduct, and analysis. New York: Oxford University Press, 1986.

v, ix, ch14, ch15

85. Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: Results from the head-to-head MOTION study. Curr Med Res Opin. 2008; 1:207–213.

ch18

86. Mills JL. Data torturing. N Engl J Med. 1993; 329:1196–1199.

ch16

87. Moher D. CONSORT: An evolving tool to help improve the quality of reports of randomized controlled trials. JAMA. 1998; 279:1489–1491.

ch9

(p.255) 88. Mount FW, Ferebee SH. Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin-para-aminosalicylic acid in pulmonary tuberculosis therapy: II. Report on twenty-week observations on 390 patients with streptomycin-susceptible infections. Am Rev Tuberc. 1953a; 67:108–113.

ch1

89. Mount FW, Ferebee SH. Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin-para-aminosalicylic acid in pulmonary tuberculosis therapy: III. Report on twenty-eight-week observations on 649 patients with streptomycin-susceptible infections. Am Rev Tuberc. 1953b; 67:539–543.

ch1

90. Mount FW, Ferebee SH. Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin-para-aminosalicylic acid in pulmonary tuberculosis therapy: I. Report on twelve-week observations on 526 patients. Am Rev Tuberc. 1952; 66:632–635.

ch1

91. Multiple Risk Factor Intervention Trial Research Group. Statistical design considerations in the NHLI Multiple Risk Factor Intervention Trial (MRFIT). J Chronic Dis. 1977; 30:261–275.

ch1

92. Murray JAH, Bradley H, Craigie WA, Onion CT, eds. The Oxford English dictionary:A new English dictionary on historical principles (13 vols.). Oxford: Clarendon Press, 1970.

ch10

93. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical principles and guidelines for the protection of human subjects of research. No. 1983–381–132:3205. Washington, DC: US Government Printing Office, 1979.

ch8, ch23

94. U.S. Congress. National Institutes of Health Revitalization Act of1993. §131, Pub L No 103–43, 107 Stat 133 (codified at 42 USC §289a-2).

ch7

95. National Institutes of Health Department of Health and Human Services: NIH Guidelines on the inclusion of women and minorities as subjects in clinical research. Federal Register. March 28 1994; 59:14508–14513.

ch7

96. National Institutes of Health. NIH Almanac. Publ. no. 81–5. Bethesda, MD: Division of Public Information, 1981b.

ch1

(p.256) 97. Neaton JD, Bartsch GE, Broste SK, Cohen JD, Simon NM, for the MRFIT Research Group. A case of data alteration in the Multiple Risk Factor Intervention Trials (MRFIT). Control Clin Trials. 1991; 12:731–740.

ch10

98. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infraction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457–2471.

ch18

99. O’Brien PC. Data and safety monitoring. In Encyclopedia of biostatistics, vol. 2, pp. 1058–1066. Chichester: John Wiley & Sons, 1998.

ch23

100. Office for Protection from Research Risks. Code of Federal Regulations, Title 45: Public Welfare, Part 46: Protection of Human Subjects. Bethesda, MD: Department of Health and Human Services, National Institutes of Health, revised 18 June 1991.

ch9, ch23

101. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, for the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA. 2008; 300:2134–2141.

ch19

102. Packard FR. Life and times of Ambroise Paré, 1510–1590. New York: Paul B Hoeber, 1921.

ch19

103. Patulin Clinical Trials Committee (of the Medical Research Council). Clinical trial of Patulin in the common cold. Lancet. 1944; 2:373–375.

ch1

104. Peto R, Collins R, Sackett D, Darbyshire J, Babiker A, Buyse M, Stewart H, Baum M, Goldhirsh A, Bonadonna G, Valagussa P, Rutqvist L, Elbourne D, Davies C, Dalesio O, Parmar M, Hill C, Clarke M, Gray R, Doll R: The trials of Dr. Bernard Fisher: A European perspective on an American episode. Control Clin Trials. 1997; 18:1–13.

ch10

105. Physicians’ Health Study Research Group Steering Committee. Preliminary report: Findings from the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1988; 318:262–264.

ch1, ch23

106. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips T, Lubin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW for the AFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354:899–910.

(p.257) ch13

107. Pruitt Jr. BA, Pruitt JH, Davis JH. Chapter 1, pp. 1–19. In Moore EE, Felficiano DV, Mattox KL, eds., Trauma (5th edition). New York: McGraw-Hill Professional, 2003.

ch19

108. Rennie D. Clinical trial misconduct. In Wiley encyclopedia of clinical trials. New York: John Wiley & Sons, 2007. Online at http://mrw.interscience.wiley.com/emrw/9780199742967/wect/article/eoct060/current/pdf

ch10

109. Rennie D. How to report randomized controlled trials: The CONSORT statement. JAMA. 1996; 276:649.

ch9

110. Ries LAG. Childhood cancer mortality. In Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, eds. Cancer incidence and survival among children and adolescents: United States SEER program: 1975–1995, pp. 165–170. SEER Monograph, Pub. No. 99–4649. Bethesda, MD: National Cancer Institute, 1999.

ch22

111. Rheumatic Fever Working Party of the Medical Research Council of Great Britain and the Subcommittee of Principal Investigators of the American Council of Rheumatic Fever and Congenital Heart Disease, American Heart Association. The evolution of rheumatic heart disease in children: Five year report of a cooperative clinical trial of ACTH, cortisone and aspirin. Circulation. 1960; 22:503–515.

ch1

112. Robinson D, Shettles L. The use of diethylstilbestrol in threatened abortion. Am J Obstet Gynecol. 1952; 63:1330–1333.

ch24

113. Savulescu J, Chalmers I, Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. Br Med J. 1996; 313:1390–1393.

ch19

114. Shuster E. Fifty years later: The significance of the Nüremberg Code. N Engl J Med. 1997; 337:1436–1440.

ch8

115. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiological data. Prev Med. 1991; 20:47–63.

ch1

(p.258) 116. Titus SL, Rhoades LJ. Repairing research integrity. Nature. 2008; 453:980–982.

ch10, ch11

117. Thomas KJ, MacPherson H, Trope L, Brazier J, Fitter M, Campbell MJ, Roman M, Walters SJ, Nicholl J: Randomised controlled trial of a short course of traditional acupuncture compared with usual care for persistent non-specific low back pain. BMJ. 2006; 333:623.

ch13

118. Tucker WB. The evolution of the cooperative studies in the chemotherapy of tuberculosis of the Veterans Administration and Armed Forces of the USA: An account of the evolving education of the physician in clinical pharmacology. Adv Tuberc Res. 1960; 10:1–68.

ch1

119. United States Congress (103rd; 1st session). NIH Revitalization Act of 1993, 42 USC § 131 (1993); Clinical Research Equity Regarding Women and Minorities; Part I: Women and Minorities as Subjects in Clinical Research. 1993.

ch11

120. United States Congress (87th): Drug Amendments of 1962, Public Law 87–781, S 1522. Washington, DC, Oct 10, 1962.

ch1

121. United States Supreme Court. Forsham et al. versus Harris, Secretary of Health, Education and Welfare, et al. Certiorari to the United States Court of Appeals for the District of Columbia Circuit. No. 78–1118, argued Oct 31, 1979, decided March 3, 1980.

ch15, ch23

122. University Group Diabetes Program Research Group. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VIII. Evaluation of insulin therapy: Final report. Diabetes. 1982; 31(Suppl 5):1–81.

ch4

123. University Group Diabetes Program Research Group. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VII. Mortality and selected nonfatal events with insulin treatment. JAMA. 1978;240:37–42.

ch1, ch3

124. University Group Diabetes Program Research Group. A Study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes:V. Evaluation of Phenformin therapy. Diabetes. 1975; 24 (Suppl 1):65–184.

ch4

(p.259) 125. University Group Diabetes Program Research Group. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: I. Design, methods, and baseline characteristics. Diabetes. 1970; 19(Suppl 2):747–783.

ix, ch3, ch4, ch19

126. University Group Diabetes Program Research Group. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results. Diabetes 1970; 19(Suppl 2):785–830.

ch1, ch19

127. U.S. Preventive Services Task Force. Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and Rationale. Ann Inter Med. 2002; 136:157–160.

ch19

128. Vuthipongse P, Bhadrakom C, Chaisilwattana P, Roongpisuthipong A, Chalermchokcharoenkit A Chearskul S, Wanprapa N, Chokephaibulkit K, Tuchipda M, Wasi C, Chuachoowong R, Siriwasin W, Chinayon P, Asavapiriyanont S, Chotpitayasunondh T, Waranawat N, Sangtaweesin V, Horpaopan S, Queen Sirikit: Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission – Thailand, 1996–1998. MMWR. 1998; 47:151–153.

ch11

129. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P: Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008 Jan 23.

ch18

130. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2002; 288:321–333.

ch1, ch3, ch15

131. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991; 266:93–98.

ch17

132. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DA. Issues in the registration of clinical trials. JAMA. 2007; 297:2112–2120.

ch9 (p.260)